axogen

The study is independent and not sponsored by Axogen. "The mainstay of management for neuroma-related pain lies in prevention." That is the conclusion of the authors of a recent study of patients undergoing en bloc skeletal or soft tissue tumor resection, 50% of whom developed neuropathic pain and 25% of whom met the criteria for diagnostic neuroma. To read this full study visit https://hubs.la/Q02LMvd-0 These links will navigate you away from Axogen’s website. Links outside Axogen’s website are provided as a resource to the viewer. Axogen accepts no responsibility for or control over the content of the linked sites.

Materials matter! This recently published study demonstrates how the body can respond differently to different conduit materials used in nerve repair. Read the paper here: https://hubs.la/Q02LSNXT0 These links will navigate you away from Axogen’s website. Links outside Axogen’s website are provided as a resource to the viewer. Axogen accepts no responsibility for or control over the content of the linked sites.

Have you registered for our upcoming Bridging the Gap event? Join us Tuesday, August 20 from 8:30 - 9:30 pm EST to discuss amputation intervention and phantom limb pain, nerve transfers, and decompression as well as building your referral network. To register, email events@axogeninc.com or ask your Axogen representative for details.

Come experience the latest innovations in nerve protection and repair at the ASSH annual meeting. Reserve your time now for a hands-on cadaveric micro skills experience that will let you see and learn how they can make a difference for your patients. https://hubs.la/Q02LChpx0

Axogen welcomes Michael Dale, CEO, who has over 30 years of experience leading transformative, high-technology medical device companies in the cardiovascular, neuromodulation, diabetes, and electrophysiology markets. “It is with pride and excitement that I embark today on a new mission as leader of Axogen,” he said. “I have been fortunate to be a part of many great healthcare businesses throughout my career. Each has been dedicated to fulfilling a credible business purpose based on unique advantages, hallmarks of a successful business. Axogen’s technologies and dedication to restoring peripheral nerve health and improving quality of life for patients who have lost sensory and or motor control function through trauma or disease embodies a unique combination of credible purpose and technological advantage. This is why I am excited to join Axogen.” https://lnkd.in/eBZNdQF6

In the evolving world of peripheral nerve surgery, non-transected nerve injuries remain challenging. Axogen and ASSH invite you to watch an expert panel of nerve surgeons discuss their decision-making process, surgical treatment approach and how they incorporate different nerve protection solutions to optimize patient outcomes. Watch now; https://hubs.la/Q02Jy_fD0 These links will navigate you away from Axogen’s website. Links outside Axogen’s website are provided as a resource to the viewer. Axogen accepts no responsibility for or control over the content of the linked sites.

A new clinical study on patients with chronic ilioinguinal nerve compression found that those with preoperative pain had intraneural fibrosis, with its severity positively correlated with pain duration. This provides a crucial functional insight not seen in pre-clinical models, highlighting the significance of intraneural collagen deposition in pain resulting from chronic nerve compression. https://hubs.la/Q02JfY8N0 These links will navigate you away from Axogen’s website. Links outside Axogen’s website are provided as a resource to the viewer. Axogen accepts no responsibility for or control over the content of the linked sites.

Axogen is hiring! Join our team! We're hiring a Region Sales Director for our Ohio/Michigan region. Here's the link to apply:

We’ve got the ulnar nerve COVERED! On June 12th Dr. Crosby of the Indiana Hand to Shoulder Center implanted that center's first Axoguard HA+ Nerve Protector™ as part of the COVERED study. This study is designed to evaluate the performance of Axoguard HA+ in first-revision cubital tunnel syndrome decompression. We are excited to share our findings as we continue to examine patient outcomes associated with nerve protection.

We’re excited to see that a new systematic review and meta-analysis comparing direct repair (DR) and connector-assisted repair (CAR) has published! This study demonstrated that for repair of nerve injuries with gaps ≤3mm, CAR had a significantly greater proportion of patients achieve meaningful recovery (≥S3 on the MRCC scale) compared to DR ( 96.1% vs. 81.3%, respectively, p<0.0001). These findings advocate for the CAR method and underscore the potential benefits of adopting the CAR technique in clinical practice. To read the publication, visit https://hubs.la/Q02GKPvy0. This link will navigate you away from Axogen. Links are provided as a resource and Axogen accepts no responsibility for or control over the content of linked sites.